Longitudinal Efficacy and Safety Study of Tolvaptan on Autosomal Dominant Polycystic Kidney Disease Patients (LET-PKD Study).
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Tolvaptan (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Therapeutic Use
- Acronyms LET-PKD
- 16 Feb 2018 Planned End Date changed from 31 Mar 2018 to 30 Sep 2021.
- 16 Feb 2018 Planned primary completion date changed from 31 Mar 2017 to 31 Mar 2020.
- 16 Feb 2018 Status changed from recruiting to active, no longer recruiting.